3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Other solid neoplasm
1
Gynecologic
1
Breast
1
Conditions
Glioma
4
Glioblastoma
4
Astrocytoma
3
Neoplasms
2
Lung Neoplasms
2
Leukemia, Lymphocytic, Chronic, B-Cell
2
Epstein-Barr Virus Infections
2
Breast Neoplasms
2
Wilms Tumor
1
Triple Negative Breast Neoplasms
1
Testicular Neoplasms
1
Sezary Syndrome
1
Recurrence
1
Primary Myelofibrosis
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Pleural Effusion, Malignant
1
Pdgfra-Associated Chronic Eosinophilic Leukemia
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Neuroblastoma
1
Myeloproliferative Disorders
1
Mycosis Fungoides
1
Multiple Myeloma
1
Mesothelioma
1
Lymphoma, T-Cell, Cutaneous
1
Lymphoma, Non-Hodgkin
1
Lymphoma, Mantle-Cell
1
Lymphoma, Large-Cell, Immunoblastic
1
Lymphoma, Large B-Cell, Diffuse
1
Lymphoma, Follicular
1
Interventions
Pemetrexed
23
Cisplatin
19
Nivolumab
8
Gemcitabine
7
Ipilimumab
6
Carboplatin
6
pembrolizumab
4
Bevacizumab
4
tazemetostat
3
durvalumab
3
Fluorouracil
3
Drug Therapy
3
spartalizumab
2
olaparib
2
niraparib
2
budigalimab
2
belinostat
2
anetumab ravtansine
2
amatuximab
2
Vinorelbine
2
Radiotherapy, Intensity-Modulated
2
Paclitaxel
2
PM 01183
2
Oxaliplatin
2
Imatinib Mesylate
2
Everolimus
2
Erlotinib Hydrochloride
2
Doxorubicin
2
Cyclophosphamide
2
venetoclax
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Mesothelioma
×
Valacyclovir
×
Clear all
NCT01997190
2023-08-25
MpeTK01
Candel Therapeutics, Inc.
Phase 1
Completed
19 enrolled